Expert Opinion on Drug Safety

Gastrointestinal safety of paracetamol: is there any cause for concern?
pp. 269-272(4)
Author: Bannwarth B.

Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus
pp. 273-278(6)
Authors: Horizon A.A.; Wallace D.J.

Safety of hydroxyurea in the treatment of HIV infection
pp. 279-288(10)
Authors: Lori F.; Kelly L.M.; Foli A.; Lisziewicz J.

Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis
pp. 289-303(15)
Author: Francis G.

Safety of growth hormone replacement therapy in adults
pp. 305-316(12)
Authors: Gibney J.; Johannsson G.

Efficacy and safety of trastuzumab
pp. 317-327(11)
Authors: Jones R.L.; Smith I.E.

Causality assessment in drug-induced hepatotoxicity
pp. 329-344(16)
Authors: Andrade R.J.; Camargo R.; Lucena M.I.; González-Grande R.

Safety of verteporfin for treatment of subfoveal choroidal neovascular membranes associated with age-related macular degeneration
pp. 345-361(17)
Authors: Gaynes B.I.; Fiscella R.G.

Patients’ role in reporting adverse drug reactions
pp. 363-368(6)
Authors: van Grootheest K.; de Jong-van den Berg L.

Safety of droperidol in behavioural emergencies
pp. 369-378(10)
Authors: Shale J.H.; Shale C.M.; Mastin W.D.

Strategies for more effective and reliable ADME
pp. 379-380(2)
Author: Rendic S.